HC Wainwright reiterated their buy rating on shares of AEON Biopharma (NASDAQ:AEON - Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target price on the stock.
AEON Biopharma Price Performance
Shares of AEON Biopharma stock traded down $0.07 during mid-day trading on Monday, hitting $1.63. 218,385 shares of the stock were exchanged, compared to its average volume of 67,325. AEON Biopharma has a twelve month low of $1.38 and a twelve month high of $17.17. The company has a 50-day simple moving average of $9.32 and a 200 day simple moving average of $7.62.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last announced its earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter. Equities analysts predict that AEON Biopharma will post -1.18 earnings per share for the current year.
Institutional Trading of AEON Biopharma
An institutional investor recently bought a new position in AEON Biopharma stock. Formidable Asset Management LLC bought a new stake in AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 64,311 shares of the company's stock, valued at approximately $360,000. Formidable Asset Management LLC owned 0.72% of AEON Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 22.78% of the company's stock.
About AEON Biopharma
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Featured Articles
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
